Castleman Disease
12
4
6
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
8.3%
1 terminated out of 12 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
67%
2 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (12)
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
Sirolimus in Previously Treated Idiopathic Multicentric Castleman Disease
International Registry for Patients With Castleman Disease
AutoInflammatory Disease Alliance Registry (AIDA)
An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context
Nintedanib Treatment in Unicentric Castleman Disease
HHV8 and Solid Organ Transplantation
Unicentric Form of Castleman Disease - Surgery Therapy Benefit
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Unlock the Cell: Castleman's Disease Flow Cytometry Study
Castleman Disease Collaborative Network Biobank
Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors